“These data build on earlier studies that demonstrated the mechanism of IO102 and IO103,” said
The data presented in the AACR poster are from two different animal tumor models and show that vaccines targeting IDO1 and PD-L1 expressing cells can cooperatively reduce tumor growth with each contributing to the anti-tumor effect through distinct molecular pathways. Where high levels of IDO1 and PD-L1 expression were seen in the tumor microenvironment (TME), the IDO1 vaccine predominantly reduced myeloid-derived immune suppression, while the PD-L1 vaccine enhanced anti-tumor T-effector functions. In contrast, where IDO1 and PD-L1 expression was lower, the IDO1 vaccine resulted in a clear increase in T cell infiltration and activation and the PD-L1 vaccine impacted the myeloid cell compartment. While further studies are needed to fully discern the relationship between IDO1+/PD-L1+ target populations within the TME and the impact of IDO1/PD-L1 targeted vaccination, our data support the use of a dual antigen approach to reduce the immunosuppression and enhance anti-tumor effect.
The poster can be found on the “Posters & Publications” page of the
Title: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models
Abstract Number: 4094
Time:
Presenter: Marion Chapellier, Ph.D., Senior Scientist R&D and translational research
About IO102-IO103
IO102-IO103 is an investigational, off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1) cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors.
The clinical trials are sponsored by
KEYTRUDA® is a registered trademark of
About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial
IOB-013/KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma, being conducted in collaboration with Merck. Patients have been enrolled from centers across
About
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim and primary analyses of the company’s Phase 3 trial, current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law,
Contact:
617-710-7305
mci@iobiotech.com
Source:
2024 GlobeNewswire, Inc., source